Product Images Topiramate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Topiramate NDC 51655-606 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 51655 606 26 Master Bottle Label Approval Rev A 05 20

Label - 51655 606 26 Master Bottle Label Approval   Rev A 05 20

This is a description of a medication package containing 90 film-coated tablets of Topiramate USP, 50 mg each. The tablets are stored in an original container and must be kept at a temperature range of 20°C to 25°C to protect them from moisture. The package has a National Drug Code (NDC) of 51655-606-26 and a lot number of 0000000000. This medicine is only available with a prescription because it is labeled as Rx Only. The dosage is specified on the package insert. The package was repackaged by Northwind Pharmaceuticals from a package with NDC 69097-123-15 manufactured by Cipla USA, Inc. The other details are not available due to errors.*

topi - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 01

topi - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 01

Topi - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 02

Topi - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 02

This appears to be a graph or chart displaying the cumulative rates for time to the first seizure among participants taking different doses of topiramate. The x-axis shows time in days and the y-axis shows the cumulative rate. The two lines on the graph represent two different doses of topiramate (50mg/day and 400mg/day), with the higher dose appearing to have a slightly faster time to first seizure.*

Figure 2: Reduction in 4-Week Migraine Headache Frequency(Studies 10 and 11 for Adults and Adolescents) - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 03

Figure 2: Reduction in 4-Week Migraine Headache Frequency(Studies 10 and 11 for Adults and Adolescents) - ccb7a1e4 a3a1 4a0e 8eb0 8086f53e314b 03

The text describes the change in the average monthly migraine period rate in a double-blind study after taking either 100 or 200 milligrams per day of Topamax medication. The text includes statistical significance levels denoted by asterisks, however, there is incomplete information to interpret the result.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.